|Bid||11.30 x 0|
|Ask||11.40 x 0|
|Day's Range||10.70 - 11.00|
|52 Week Range||9.16 - 25.38|
|Beta (3Y Monthly)||0.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Revance Therapeutics Inc is a clinical-stage biopharmaceutical company. Revance Therapeutics Inc had annual average EBITDA growth of 21.60% over the past five years. Warning! GuruFocus has detected 5 Warning Signs with RVNC.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year. More than 95 percent of patients administered with Revance's long-acting neuromodulator injection RT002 were found to have none or mild frown lines after four weeks, according to data from the third late-stage study. The treatment, which requires two or less doses a year, was effective in maintaining reduced wrinkle severity in patients for a median duration of 24 weeks.
If you’re interested in Revance Therapeutics Inc (NASDAQ:RVNC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...